Impact of renal impairment on outcomes with lenalidomide and dexamethasone treatment in the FIRST trial, a randomized, open-label phase 3 trial in transplant-ineligible patients with multiple myeloma

Renal impairment is associated with poor prognosis in myeloma. This analysis of the pivotal phase 3 FIRST trial examined the impact of renally adapted dosing of lenalidomide and dexamethasone on outcomes of patients with different degrees of renal impairment. Transplant-ineligible patients not requi...

詳細記述

書誌詳細

主要な著者:	Meletios A. Dimopoulos, Matthew C. Cheung, Murielle Roussel, Ting Liu, Barbara Gamberi, Brigitte Kolb, H. Guenter Derigs, HyeonSeok Eom, Karim Belhadj, Pascal Lenain, Richard Van der Jagt, Sophie Rigaudeau, Mamoun Dib, Rachel Hall, Henry Jardel, Arnaud Jaccard, Axel Tosikyan, Lionel Karlin, William Bensinger, Rik Schots, Nicolas Leupin, Guang Chen, Jennifer Marek, Annette Ervin-Haynes, Thierry Facon
フォーマット:	Artigo
言語:	Inglês
出版事項:	Ferrata Storti Foundation 2016-03-01
シリーズ:	Haematologica
オンライン･アクセス:	https://haematologica.org/article/view/7655
タグ:	タグ追加 タグなし, このレコードへの初めてのタグを付けませんか!